2m 2m 2m 2m 2m 2m 2m
Endexx (EDXC)
OTC
$0.000001$0.00 (0.00%)
Price as of Jun 03, 2026- $57,185.00Market Cap
- -99.97%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Endexx (EDXC)
$0.000001$0.00 (0.00%)
Annual
Quarterly
09/30/2022 | 09/30/2021 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 2.1M +228.66% | 650,515 N/A | |
Cost of Revenue | 766,558 +30.13% | 589,056 N/A | |
Gross Profit | 1.2M +446.76% | -344,078 N/A | |
Sales and Marketing Expense | 594,874 -66.54% | 1.8M N/A | |
Research and Development Expense | -27,066 +166.79% | -10,145 N/A | |
Depreciation and Amortization Expense | 20,606 +1.01% | 20,400 N/A | |
Total Operating Expenses | 5.1M +1.64% | 5.0M N/A | |
Operating Profit | -3.9M -27.08% | -5.4M N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | -1.2M +30.65% | -950,549 N/A | |
Interest Income and Expense and Net | -1.2M +30.65% | -950,549 N/A | |
Total Nonoperating Income and Expense | -1.2M -14.55% | -1.4M N/A | |
Income before Taxes | -3.9M -27.08% | -5.4M N/A | |
Income Taxes | N/A N/A | N/A N/A | |
Extraordinary Items | 427,902 +5.51% | 405,537 N/A | |
Net Income | -4.9M -28.26% | -6.8M N/A | |
Net Income from Continuing Operations Applicable to Common | -4.9M -28.26% | -6.8M N/A | |
Basic EPS and Net Income | -0.01 0.00% | -0.01 N/A | |
Diluted EPS and Net Income | -0.01 0.00% | -0.01 N/A | |
Basic Weighted Average Shares | 504.0M +10.75% | 455.0M N/A | |
Diluted Weighted Average Shares | 504.0M +10.75% | 455.0M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 656,776 +3,047.44% | 20,867 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 656,776 +3,047.44% | 20,867 N/A | |
Total Current Assets | 3.4M +226.11% | 1.0M N/A | |
Accumulated Depreciation | 77,044 +2.20% | 75,388 N/A | |
Property and Plant and Equipment and Net | 48,005 -89.32% | 449,661 N/A | |
Total Long-Term Assets | 48,425 -89.46% | 459,581 N/A | |
Total Assets | 13.3M +654.49% | 1.8M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 5.4M -18.49% | 6.7M N/A | |
Total Current Liabilities | 18.4M +59.88% | 11.5M N/A | |
Total Long-Term Debt | 4.6M +1,748.40% | 248,200 N/A | |
Total Long-Term Liabilities | 4.6M +1,748.40% | 248,200 N/A | |
Total Liabilities | 23.0M +95.56% | 11.7M N/A | |
Retained Earnings | -44.4M +12.36% | -39.5M N/A | |
Total Stockholders Equity | -11.4M +14.48% | -10.0M N/A | |
Total Shares Outstanding | 501.4M +3.10% | 486.3M N/A | |
Cash Flow | |||
Cash from Operating Activities | -2.1M -43.87% | -3.7M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | -573,763 N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 3.3M -11.74% | 3.7M N/A | |
Financials Ratio | |||
Gross Margin | 64.15% N/A | N/A N/A | |
Operating Margin | -183.20% N/A | N/A N/A | |
Return on Assets | -64.96% N/A | N/A N/A | |
Return on Equity | 45.61% N/A | N/A N/A | |
Revenue Growth | 228.66% N/A | N/A N/A | |
Current Ratio | 0.18 N/A | N/A N/A | |
Cash Ratio | 0.04 N/A | N/A N/A | |
Debt-to-Equity Ratio | -0.88 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.75 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow